Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


29.10.2018

1 AJR Am J Roentgenol
2 BJU Int
2 BMC Cancer
1 Br J Cancer
1 Cancer Lett
4 Eur Urol
2 Int J Urol
1 J Cell Physiol
5 J Urol
1 Mod Pathol
2 Oncogene
2 Oncol Rep
1 Oncology (Williston Park)
1 PLoS One
1 Prog Urol
3 Prostate


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. TURCO S, Lavini C, Heijmink S, Barentsz J, et al
    Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study.
    AJR Am J Roentgenol. 2018;211:W242-W251.
    PubMed     Text format     Abstract available


    BJU Int

  2. ONG WL, Yaxley JW, Millar JL
    Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer - time to reverse the declining trend?
    BJU Int. 2018 Oct 19. doi: 10.1111/bju.14487.
    PubMed     Text format    

  3. CHANDRASEKAR T, Dall'Era MA, Tilki D
    Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer.
    BJU Int. 2018;122:721-722.
    PubMed     Text format    


    BMC Cancer

  4. IVANOVIC RF, Viana NI, Morais DR, Moura C, et al
    miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.
    BMC Cancer. 2018;18:992.
    PubMed     Text format     Abstract available

  5. MARTINEZ-GONZALEZ NA, Neuner-Jehle S, Plate A, Rosemann T, et al
    The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1015.
    PubMed     Text format     Abstract available


    Br J Cancer

  6. TEO MY, Scher HI
    Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0239.
    PubMed     Text format     Abstract available


    Cancer Lett

  7. GRUNDEMANN C, Huber R
    Chemoprevention with isothiocyanates - From bench to bedside.
    Cancer Lett. 2018;414:26-33.
    PubMed     Text format     Abstract available


    Eur Urol

  8. ZAFEIRIOU Z, Bianchini D, Chandler R, Rescigno P, et al
    Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
    Eur Urol. 2018 Oct 16. pii: S0302-2838(18)30738.
    PubMed     Text format     Abstract available

  9. ANTONARAKIS ES, Shaukat F, Isaacsson Velho P, Kaur H, et al
    Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30750.
    PubMed     Text format     Abstract available

  10. VAN DEN BROECK T, van den Bergh RCN, Arfi N, Gross T, et al
    Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30752.
    PubMed     Text format     Abstract available

  11. GANDAGLIA G, Ploussard G, Valerio M, Mattei A, et al
    A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
    Eur Urol. 2018 Oct 17. pii: S0302-2838(18)30753.
    PubMed     Text format     Abstract available


    Int J Urol

  12. POELAERT F, Schatteman P, Lumen N
    Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Oct 22. doi: 10.1111/iju.13837.
    PubMed     Text format    

  13. SAVELLI G, Zaniboni A, Stefanelli A
    Re: Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Oct 24. doi: 10.1111/iju.13832.
    PubMed     Text format    


    J Cell Physiol

  14. SAGREDO AI, Sagredo EA, Pola V, Echeverria C, et al
    TRPM4 channel is involved in regulating epithelial to mesenchymal transition, migration, and invasion of prostate cancer cell lines.
    J Cell Physiol. 2018 Oct 21. doi: 10.1002/jcp.27371.
    PubMed     Text format     Abstract available


    J Urol

  15. RESNICK MJ
    Re: Quality of Life during Treatment with Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Urol. 2018;200:936.
    PubMed     Text format    

  16. TANEJA SS
    Re: Circulating microRNAs and Treatment Response in the Phase II SWOG S0925 Study for Patients with New Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2018;200:944-946.
    PubMed     Text format    

  17. TANEJA SS
    Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide.
    J Urol. 2018;200:945.
    PubMed     Text format    

  18. TANEJA SS
    Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate Cancer.
    J Urol. 2018;200:945-946.
    PubMed     Text format    

  19. CHEN SL, Fann JC, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA).
    J Urol. 2018 Oct 23. pii: S0022-5347(18)44024-4. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Mod Pathol

  20. HOLLEMANS E, Verhoef EI, Bangma CH, Rietbergen J, et al
    Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.
    Mod Pathol. 2018 Oct 22. pii: 10.1038/s41379-018-0157.
    PubMed     Text format     Abstract available


    Oncogene

  21. SU F, Ahn S, Saha A, DiGiovanni J, et al
    Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance.
    Oncogene. 2018 Oct 25. pii: 10.1038/s41388-018-0558.
    PubMed     Text format     Abstract available

  22. PROBERT C, Dottorini T, Speakman A, Hunt S, et al
    Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis.
    Oncogene. 2018 Oct 23. pii: 10.1038/s41388-018-0540.
    PubMed     Text format     Abstract available


    Oncol Rep

  23. WANG H, Huang W, Yu X, Li W, et al
    Two prostate cancerassociated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6810.
    PubMed     Text format     Abstract available

  24. TANG Y, Wu B, Huang S, Peng X, et al
    Downregulation of miR5053p predicts poor bone metastasisfree survival in prostate cancer.
    Oncol Rep. 2018 Oct 25. doi: 10.3892/or.2018.6826.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  25. WALTON-DIAZ A, Rais-Bahrami S
    When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer.
    Oncology (Williston Park). 2018;32:501-4.
    PubMed     Text format     Abstract available


    PLoS One

  26. WU X, Zhang K, Chen Y, Wang R, et al
    Theoretical and experimental study of dual-fiber laser ablation for prostate cancer.
    PLoS One. 2018;13:e0206065.
    PubMed     Text format     Abstract available


    Prog Urol

  27. PATARD PM, Roumiguie M, Prudhomme T, Doumerc N, et al
    Migration in last decade to high-risk prostate cancer after radical prostatectomy.
    Prog Urol. 2018 Oct 15. pii: S1166-7087(18)30557.
    PubMed     Text format     Abstract available


    Prostate

  28. KRANZBUHLER B, Salemi S, Mortezavi A, Sulser T, et al
    Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23725.
    PubMed     Text format     Abstract available

  29. ESKRA JN, Schlicht MJ, Bosland MC
    Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23727.
    PubMed     Text format     Abstract available

  30. SUER I, Guzel E, Karatas OF, Creighton CJ, et al
    MicroRNAs as prognostic markers in prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23731.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: